Chemotherapy and antiangiogenesis--drug-specific, dose-related effects.
Acta Oncol
; 42(4): 294-303, 2003.
Article
en En
| MEDLINE
| ID: mdl-12899500
Dose-response effects of fluorouracil, paclitaxel, doxorubicin, cisplatin, methotrexate, cyclophosphamide and etoposide on VEGF165/164-mediated angiogenesis using the rat mesenteric-window angiogenesis assay are reported. VEGF is a pivotal pro-angiogenic factor in most tumors. Microvessel spatial extension, density, pattern formation and segment length were assessed quantitatively and objectively. A single i.v. injection of each drug was given at a low, intermediate or high dose, 7 days before sacrifice. All the drugs elicited significant responses in terms of one or more measured variables. Only paclitaxel, doxorubicin and cyclophosphamide significantly suppressed the overall angiogenic response (p < or = 0.0001, p < or = 0.0002 and p < or = 0.05, respectively), however. Taking toxicity into account, paclitaxel was more potent in inhibition of angiogenesis than the other agents. No clear correlation was found between drug half-life, the degree of toxic effects (in terms ofbody weight changes) and the antiangiogenic effect. The antiangiogenic effects were distinctly drug specific.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Neovascularización Fisiológica
/
Mesenterio
/
Antineoplásicos
Idioma:
En
Revista:
Acta Oncol
Año:
2003
Tipo del documento:
Article
País de afiliación:
Suecia